Paweł Wiechno

TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.

TL;DR: Radium-223 treatment did not seem to significantly reduce the risk of symptomatic pathological bone fracture, or the need for tumour-related orthopaedic surgical intervention, but should be considered as a treatment option for patients with castration-resistant prostate cancer and symptomatic bone metastases.

TL;DR: The overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab ( a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma was assessed.

TL;DR: Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer and preclinical data suggest synergy between olaparIB and androgen pathway inhibitors.

TL;DR: PURPOSEPembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types The phase II KEYNOTE-427 study evaluated efficacy as discussed by the authors.